Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-07-01EMA Withdrawn: Mulpleo (previously Lusutrombopag Shionogi) (Lusutrombopag) — Shionogi B.V.
Mulpleo (lusutrombopag) has been withdrawn by Shionogi B.V. for thrombocytopenia.
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant [NA]
This clinical trial update indicates that the study evaluating a donor stem cell boost for patients with low blood cell counts after a donor…
-
CLINICAL_TRIALS withdrawal · 2016-10-24Clinical Trial Update: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis [EARLY_Phase 1]
Northwestern University’s early-phase trial of siltuximab for myelofibrosis, including primary, post-polycythemia vera, and post-essential t…
-
CLINICAL_TRIALS withdrawal · 2015-05-13Clinical Trial Update: Milk-only Lactation Study for Patients on Eltrombopag [Phase 4]
A Phase 4 trial evaluating a milk-only lactation protocol for patients on eltrombopag has been withdrawn.
-
EMA withdrawal · 2012-07-27EMA Withdrawn: Refludan (lepirudin) — Celgene Europe Ltd.
EMA withdrew Refludan (lepirudin) from the market in 2012, with thromboembolism and thrombocytopenia as therapeutic areas.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.